DEBRISOQUINE 4-HYDROXYLASE (CYP2D) LOCUS AND POSSIBLE SUSCEPTIBILITY TO SCHIZOPHRENIA

被引：20
|
作者：
VALLADA, H
COLLIER, D
DAWSON, E
OWEN, M
NANKO, S
MURRAY, R
GILL, M
机构：
[1] TEIKYO UNIV,SCH MED,DEPT PSYCHIAT,TOKYO 173,JAPAN
[2] UNIV WALES COLL MED,DEPT PSYCHOL MED,CARDIFF CF4 4XN,S GLAM,WALES
来源：
LANCET | 1992年 / 340卷 / 8812期
关键词：
D O I：
10.1016/0140-6736(92)93266-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：181 / 182
页数：2
相关论文
共 50 条
  • [11] Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression
    Schulz-Utermoehl, T
    Bennett, AJ
    Ellis, SW
    Tucker, GT
    Boobis, AR
    Edwards, RJ
    PHARMACOGENETICS, 1999, 9 (03): : 357 - 366
  • [12] DNA HAPLOTYPE DEPENDENCY OF DEBRISOQUINE 4-HYDROXYLASE (CYP2D6) EXPRESSION AMONG EXTENSIVE METABOLIZERS
    MURA, C
    PANSERAT, S
    VINCENTVIRY, M
    GALTEAU, MM
    JACQZAIGRAIN, E
    KRISHNAMOORTHY, R
    HUMAN GENETICS, 1993, 92 (04) : 367 - 372
  • [13] Genetic polymorphism and Parkinson's disease in Taiwan: Study of debrisoquine 4-hydroxylase (CYP2D6)
    Lo, HS
    Chen, CH
    Hogan, EL
    Kao, KP
    Wang, VC
    Yan, SH
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 158 (01) : 38 - 42
  • [14] Debrisoquine Metabolism and CYP2D Expression in Marmoset Liver Microsomes
    Cooke, Brian R.
    Bligh, S. W. Annie
    Cybulski, Z. Richard
    Ioannides, Costas
    Hall, Michael
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (01) : 70 - 75
  • [15] Oxidation of debrisoquine by marmoset CYP2D enzymes, CYP2D19 and CYP2D30
    Narimatsu, S
    Kuramoto, S
    Hichiya, H
    Yamamoto, S
    Asaoka, K
    Miyata, A
    Kiryu, K
    Ueda, N
    Naito, S
    Ellis, SW
    DRUG METABOLISM REVIEWS, 2003, 35 : 192 - 192
  • [16] CATALYTIC ACTIVITIES OF HUMAN DEBRISOQUINE 4-HYDROXYLASE CYTOCHROME-P450 (CYP2D6) EXPRESSED IN YEAST
    ELLIS, SW
    CHING, MS
    WATSON, PF
    HENDERSON, CJ
    SIMULA, AP
    LENNARD, MS
    TUCKER, GT
    WOODS, HF
    BIOCHEMICAL PHARMACOLOGY, 1992, 44 (04) : 617 - 620
  • [17] GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS
    DAHL, ML
    YUE, QY
    ROH, HK
    JOHANSSON, I
    SAWE, J
    SJOQVIST, F
    BERTILSSON, L
    PHARMACOGENETICS, 1995, 5 (03): : 159 - 164
  • [18] Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark
    Dahl, AA
    Lowert, A
    Asserson, S
    Bjarking, L
    Berglund, J
    Kristensen, F
    Norum, D
    Tonseth, S
    Bayer, L
    Maehlum, E
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1998, 13 (07) : 509 - 511
  • [19] RELATIONSHIP OF CYP2D6 (DEBRISOQUINE HYDROXYLASE) GENOTYPE TO BREAST-CANCER SUSCEPTIBILITY
    BUCHERT, ET
    WOOSLEY, RL
    SWAIN, SM
    OLIVER, SJ
    COUGHLIN, SS
    PICKLE, L
    TROCK, B
    RIEGEL, AT
    PHARMACOGENETICS, 1993, 3 (06): : 322 - 327
  • [20] QUINIDINE DISCRIMINATES BETWEEN RAT AND HUMAN DEBRISOQUINE 4-HYDROXYLASE
    TU, ZG
    MURRAY, B
    SESARDIC, D
    KOBAYASHI, S
    MURRAY, S
    DAVIES, DS
    BOOBIS, AR
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 25 (05) : P674 - P674
12345